Harbour gets Chinese rights to HanAll's biologics

Korean biotech HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize HL161 and HL036 for multiple indications in China, including Hong Kong and Macau, and Taiwan. HanAll retains rights elsewhere.

HanAll is eligible to receive up to $81 million in an upfront and milestone payments, plus royalties. The partners declined to provide additional financial terms...